ArticleAmerican journal of translational research2025
Mechanical thrombectomy combined with tirofiban for treatment of acute intracranial atherosclerotic cerebral infarction: clinical observations and effect on serum inflammatory factors.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Cognitive outcomes after endovascular thrombectomy in ischemic stroke: a systematic review.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of mechanical thrombectomy (MT) combined with tirofiban in treating acute intracranial large artery atheromatous cerebral infarction and its effect on inflammatory factor levels.
methodsThis retrospective study included 102 patients with acute intracranial large atherosclerotic cerebral infarction admitted to Jili Hospital, Liuyang City, Hunan Province, between December 2022 and December 2024. Patients were divided into a control group (MT) and an observation group (MT + tirofiban). Pre-treatment and post-treatment assessments included revascularization rate, hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), D-dimer (D-D), prothrombin time (PT), activated partial thromboplastin time (APTT), neuron-specific enolase (NSE), central neural specific protein (S100β), and myelin basic protein (MBP). Neurological function was evaluated using the National Institutes of Health Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE), modified Barthel index (MBI), and Fugl-Meyer assessment (FMA). Logistic analysis was used to identify factors influencing vascular re-canalization.
resultsAfter treatment, the revascularization rate was higher in the observation group (94.12% vs. 78.43%, P<0.05). NIHSS, D-D, hs-CRP, TNF-α, IL-6, NSE, S100β, and MBP levels decreased significantly, with lower values observed in the observation group (P<0.05). MMSE, MBI, and FMA scores increased more in the observation group (P<0.05). PT and APTT were prolonged significantly, with higher values in the observation group (P<0.05). Logistic regression identified post-treatment NIHSS score as an independent risk factor for re-occlusion (P<0.05).
conclusionTirofiban combined with MT improves revascularization in patients, reduces inflammation and neurobiochemical damage, enhances neurological function, and lowers the risk of re-occlusion in patients with acute intracranial large artery atheromatous cerebral infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.